
Playing a hot hand in cancer R&D, Pfizer scores its 4th drug approval in just 2 months
Pfizer’s hot hand in oncology continued this week with an FDA OK for glasdegib, an oral drug designed to throw a monkey wrench into the biology driving the hedgehog pathway in acute myeloid leukemia.
The drug, Pfizer’s fourth oncology product approval in just two months, will now be sold as Daurismo in combination with chemo for newly diagnosed cases of AML, when patients can’t tolerate the kind of intensive chemo regime needed to rein in the blood cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.